News

Canon Medical Systems USA Inc. Announces Expansion of Distributorship with the Acquisition of NXC Imaging

Tustin, California, (GLOBE NEWSWIRE) — Canon Medical Systems USA Inc., a commercial subsidiary of Canon Medical Systems Corporation and a global leader in innovative diagnostic imaging technology, today announces it has signed a definitive agreement to acquire NXC Imaging, a medical imaging equipment distributor and service provider headquartered in Minneapolis, Minnesota. Founded in 1964, NXC Imaging’s distributorship area spans the U.S. Upper Midwest. The acquisition is expected to close in the third quarter of the 2022 calendar year.

The addition of NXC Imaging to Canon Medical Systems USA will strengthen its sales and service channels across the Upper Midwest in Canon’s diagnostic imaging portfolio that includes modalities of Computed Tomography (CT), Positron Emission Tomography (PET), Magnetic Resonance (MR), X-ray (XR), Vascular Imaging (VL) and Ultrasound (UL). Canon Medical plans to continue building its substantial sales and service organization, offering innovative solutions and unique business models tailored to each client’s specific needs.

“We have partnered with NXC Imaging for over 33 years,” said Yuji Hamada, CEO and President of Canon Medical Systems USA Inc. “Our successful partnership has thrived due to Canon’s innovative technology and trusting collaboration with NXC’s entrepreneurial company culture. The results of our partnership have demonstrated strong results over the past 15 years in the Upper Midwest region.”

“Our company’s foundation was built on our long-term customer relationships, trust, and loyalty in our territories. As a result, we have provided exceptional technology solutions and best-in-class support. We are proud of the legacy we’ve created and know that as a part of Canon Medical, we will continue to provide the Upper Midwest region with the same “Never Ordinary” customer service we are known for,” stated Bruce Zeilinger, President, and CEO of NXC Imaging.

Read more here.

Recent News

05/22/2026

BIO Statement on Veto of Prescription Drug Affordability Boards (PDAB) in VirginiaPatrick J. Plues, Senior Vice President of State Government Affairs & Affiliate Relations at the Biotechnology Innovation Organization (BIO) released the following statement on the veto of Prescription Drug Affordability Boards (PDAB) legislation in Virginia: “BIO applauds Governor Spanberger’s decision to veto SB 271 and HB 483 — legislation that would have established a Prescription Drug Affordability Board (PDAB) and imposed arbitrary price controls in Virginia. The Governor’s action recognized an important point: even well-intentioned healthcare policies must be carefully designed to avoid unintended consequences for patients, providers, employers, and Virginia’s innovation economy. “BIO is proud to represent biotechnology companies developing the next generation of life-changing medicines, including many in the Commonwealth. We believe policymakers play a critically important role in helping advance both patient access to treatments and the continued growth of the life sciences sector. “We look forward to working with the Governor’s Administration, the General Assembly, Virginia Bio and other stakeholders to advance practical, patient-centered policy solutions that improve affordability while preserving access to care and the innovation ecosystem patients depend on.”

Patrick J. Plues, Senior Vice President of State Government Affairs & Affiliate Relations at the Biotechnology Innovation Organization (BIO) released the following statement on the veto of Prescription Drug Affordability Boards (PDAB) legislation in Virginia: “BIO applauds Governor Spanberger’s decision to veto SB 271 and HB 483 — legislation that would have established a Prescription

05/21/2026

Virginia Bio Applauds Governor Spanberger’s Veto of SB 271 and HB 483

The Virginia Biotechnology Association (Virginia Bio) today expressed strong support for Governor Abigail Spanberger’s decision to veto Senate Bill 271 and House Bill 483, legislation that would have established a Prescription Drug Affordability Advisory Panel (PDAAP) in the Commonwealth. Virginia Bio and the Virginia Chamber of Commerce sent a joint letter to Governor Spanberger commending

05/21/2026

New Global Clinical Society to Bring Focused Ultrasound Into Mainstream Medicine

The Focused Ultrasound Foundation today announced the launch of the International Focused Ultrasound Society (IFUS), a new organization dedicated to advancing clinical practice and accelerating adoption of focused ultrasound – a revolutionary, noninvasive therapeutic technology. Established as a program of the Focused Ultrasound Foundation, IFUS aggregates and expands the Foundation’s activities related to clinical implementation